Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Payables (2016 - 2025)

Immucell's Payables history spans 16 years, with the latest figure at $792217.0 for Q4 2025.

  • For Q4 2025, Payables fell 68.09% year-over-year to $792217.0; the TTM value through Dec 2025 reached $792217.0, down 68.09%, while the annual FY2025 figure was $792217.0, 68.09% down from the prior year.
  • Payables reached $792217.0 in Q4 2025 per ICCC's latest filing, down from $949654.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.6 million in Q2 2025 to a low of $1170.0 in Q2 2024.
  • Average Payables over 5 years is $1.1 million, with a median of $949654.0 recorded in 2025.
  • Peak YoY movement for Payables: plummeted 99.04% in 2024, then soared 221115.64% in 2025.
  • A 5-year view of Payables shows it stood at $726781.0 in 2021, then surged by 175.3% to $2.0 million in 2022, then crashed by 90.0% to $200000.0 in 2023, then surged by 1141.26% to $2.5 million in 2024, then tumbled by 68.09% to $792217.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Payables are $792217.0 (Q4 2025), $949654.0 (Q3 2025), and $2.6 million (Q2 2025).